Primary Ciliary Dyskinesia MedDRA version: 20.0 Level: PT Classification code 10069713 Term: Primary ciliary dyskinesia System Organ Class: 10010331 - Congenital, familial and genetic disorders
Conditions
Interventions
Product Name: VX-371 / 4.2% NaCl
Pharmaceutical Form: Inhalation solution
INN or Proposed INN: VX-371
Current Sponsor code: VX-371
Conce
Sponsors
Parion Sciences, Incorporated
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subject (or subject’s legally appointed and authorized representative) will sign and date an informed consent form (ICF) and, where appropriate, assent form. 2. Willing and able to comply with scheduled visits, treatment plan, study restrictions laboratory tests, contraceptive guidelines, and other study procedures. 3. Willing and able to use the nebulization device as directed by the instructions for use. 4. The subject must have evidence supportive of a PCD diagnosis, based on the following: A. Subjects =12 to 24 hours - Any organ laterality defect confirmed by historical chest imaging – situs inversus totalis, situs ambiguous, or heterotaxy - Daily, year-round wet or productive cough starting in first year of life or bronchiectasis on historical chest imaging - Daily, year-round nasal congestion starting in first year of life or pansinusitis on historical sinus imaging B. Subjects =18 years of age must have bronchiectasis on historical chest imaging C. All subjects must ALSO have documentation of at least one of the following historical tests: - For patients with no laterality defect, nNO level, measured with a chemiluminescent NO analyzer, during plateau <77 nL/min on 2 occasions, at least 2 months apart, with CF excluded by sweat chloride or genetic testing. - For patients with a laterality defect, nNO level, measured with a chemiluminescent NO analyzer, during plateau <77 nL/min on at least 1 occasion. - Diagnostic ciliary ultrastructural defect on transmission electron micrograph (TEM) - Two loss of function and/or known mutations in a single PCD-associated gene. Prior to randomization, all subjects must have a confirmed diagnosis of PCD (including central review, as required) based on one of the following: - 2 loss of function and/or known mutations in a single PCD-associated gene identified by the central genetic testing laboratory from the specimen obtained at the Screening Visit; previous genotype results cannot be used to determine eligibility for randomization. - Diagnostic ciliary ultrastructural defect on transmission electron micrograph. A previously prepared TEM specimen will be reviewed centrally; a new specimen will not be obtained. - Laterality defect that includes dextrocardia plus bronchiectasis in more than 1 lobe on historical chest imaging. 5. Subjects with percent predicted FEV1 of =40 to <90 percentage points adjusted for age,sex, and height according to the Global Lung Function Initiative (GLI) predicted values at the Screening Visit, taken 4 hours or more after last dose of short-acting bronchodilators (ß-agonists and/or anticholinergics) 6. Non-smoker for the past 90 days prior to the Screening Visit and less than a 5 pack-year lifetime history of smoking, and willing to not smoke while enrolled in the study. 7. Stable regimen of medications and chest physiotherapy for the 28 days prior to Day 1, and no
Exclusion criteria
Exclusion criteria: 1. Diagnosis of CF, including at least 1 of the following: a. Documented sweat chloride test =60 mM by quantitative pilocarpine iontophoresis or b. Abnormal nasal potential difference (NPD) test or c. 2 CF-causing mutations in the CFTR gene 2. Subjects with only 1 mutation in the CFTR gene and a sweat chloride test =60 mM by quantitative pilocarpine iontophoresis. 3. History of any organ transplantation or lung resection or chest wall surgery. 4. Significant congenital heart defects, other than a laterality defect, at the discretion of the investigator. 5. Diagnosis of Cri du chat syndrome (chromosome 5p deletion syndrome). 6. Inability to withhold short-acting bronchodilator use for 4 hours prior to clinic visit and long-acting bronchodilator use the night before the first and last clinic visit of each treatment period. 7. History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject. This may include, but is not limited to history of clinically significant and uncontrolled adrenal, neurologic, gastrointestinal, renal, hepatic,cardiovascular (including hyper/hypotension and tachy/bradycardia),psychological, pulmonary (other than PCD), metabolic, endocrine, or hematological/coagulation disorder or disease, or scoliosis of such severity that it impacts pulmonary function or any other major disorder or disease, in the opinion of the investigator. 8. Use of diuretics (including amiloride) or renin-angiotensin antihypertensive drugs (e.g., spironolactone, angiotensin converting enzyme [ACE] and/or neural endopeptidase [NEP]-inhibitors, or angiotensin receptor blockers [ARBs]) or trimethoprim or drospirenone in the 28 days before Day 1 or anticipate need for these medications during the study. 9. Had symptoms of acute upper or lower respiratory tract infection or had an acute pulmonary exacerbation requiring treatment or was treated with systemic antibiotics for ear or sinus disease within 28 days before Day 1 (topical otic antibiotics allowed). 10. History of significant intolerance to inhaled HS, or intolerance to the single dose of HS at the Screening Visit, as determined by the investigator. 11. History of drug or alcohol abuse, in the opinion of the investigator. 12. Known hypersensitivity to any of the study drug or amiloride. 13. Used ivacaftor within 28 days prior to Day 1 or anticipate need for ivacaftor during the study. 14. Pregnant and/or nursing females. 15. Any clinically significant laboratory abnormalities at the Screening Visit as judged by the investigator, or any of the following: a. Plasma or serum potassium > upper limit of normal (ULN) b. Abnormal renal function, defined as creatinine clearance rate 2 × ULN for total bilirubin, unless accounted for
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Part A To evaluate the safety and efficacy of treatment with VX-371, administered with and without 4.2% hypertonic saline (HS) in subjects with primary ciliary dyskinesia (PCD) who are =12 years of age. Part B To evaluate the safety and efficacy of treatment with ivacaftor and VX-371, administered with and without 4.2% HS in subjects with PCD who are =12 years of age. ; Secondary Objective: Part A To evaluate the effect of VX-371, administered with and without 4.2% HS on quality of life (QOL) in subjects with PCD who are =12 years of age. Part B To evaluate the effect of ivacaftor and VX-371 administered with and without 4.2% HS on QOL in subjects with PCD who are =12 years of age. ; Primary end point(s): Part A -Results of safety and tolerability assessments of adverse events (AEs), clinical laboratory values (urine, serum and plasma chemistry, and hematology), 12-lead electrocardiograms (ECGs), spirometry, vital signs, and pulse oximetry. -Absolute change in percent predicted FEV1, from study baseline after 28 days of treatment in Part A. Part B - Results of safety and tolerability assessments of adverse events AEs, clinical laboratory values (urine, serum and plasma chemistry, and hematology), 12-lead ECGs, spirometry, vital signs, and pulse oximetry. - Absolute change in ppFEV1 from study baseline and Part B baseline, after 28 days of treatment in Part B. ; Timepoint(s) of evaluation of this end point: Part A For TP1 it will be evaluated at day 28 and for TP2 it will be evaluated at day 85 --> both compared to study baseline Part B For Treatment Period 3 it will be evaluated at Day 113 --> compared to study baseline and Par | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Part A -Change in QOL score as measured by the PCD Quality of Life Questionnaire (QOL-PCD) and the St. George’s Respiratory Questionnaire (SGRQ) after 28 days of treatment. Part B - Change in QOL score as measured by the QOL-PCD and SGRQ, from study baseline and Part B baseline, after 28 days of treatment in Part B ; Timepoint(s) of evaluation of this end point: Part A For TP1 it will be evaluated at day 28 and for TP2 it will be evaluated at day 85 --> both compared to study baseline Part B For Treatment Period 3 it will be evaluated at Day 113 --> compared to study baseline and Part B baseline | — |
Countries
Canada, Denmark, Germany, Italy, Netherlands, Poland, United Kingdom, United States
Contacts
Public ContactClinical Operations
Parion Sciences
Outcome results
None listed